Considering this, the necessity of novel therapeutics in CRC, and the successful antitumoral activity of an anti-CD98hc ADC in triple negative breast cancer [14], we decided to explore whether CD98hc could represent an actionable target in CRC. Here, SLC3A2 is linked to triple-negative breast carcinoma.